SMILES string
FC(F)(C1=NC(C2=CC(C(NCC3(C4=NC(C5=CC=CC=C5)=CS4)CCOCC3)=O)=CC=C2)=NO1)F
assay
≥98% (HPLC)
form
powder
color
white to yellow-orange
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
Quality Level
Biochem/physiol Actions
Potent and type IIa-selective histone deacetylases (HDAC4/5/7/9) inhibitor in vitro and in vivo.
TMP269 is a potent and type IIa-selective histone deacetylases (HDACs) inhibitor (HDAC4/5/7/9 Ki = 126/80/36/19 nM, IC50 = 157/97/43/23 nM; HDAC6/8 IC50 = 8.2/4.2 μM, HADC1/2/3/10/11 IC50 >100 μM) with an active site zinc-targeting trifluoromethyloxadiazole (TFMO). TMP269 inhibits the growth of AsPC-1 by upregulating FOXO3a expression and displays in vivo therapeutic efficacy in animal models of acute kidney injury (50 mg/kg via i.p. in mice) and cerebral ischemia/reperfusion injury (1-16 mg/kg via i.p. in rats).
TMP269 is a potent and type IIa-selective histone deacetylases (HDACs) inhibitor (HDAC4/5/7/9 Ki = 126/80/36/19 nM, IC50 = 157/97/43/23 nM; HDAC6/8 IC50 = 8.2/4.2 μM, HADC1/2/3/10/11 IC50 >100 μM) with an active site zinc-targeting trifluoromethyloxadiazole (TFMO). TMP269 inhibits the growth of AsPC-1 by upregulating FOXO3a expression and displays in vivo therapeutic efficacy in animal models of acute kidney injury (50 mg/kg via i.p. in mice) and cerebral ischemia/reperfusion injury (1-16 mg/kg via i.p. in rats).
法规信息
新产品
此项目有
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持